Intratumor CpG-ODN Injection Boosters Immune Killing Against in Situ Tumor Antigen Release for Advanced Solid Tumors
Recruiting · NCT04952272 · Interventional (participants receive a specific treatment)
View the official record on ClinicalTrials.gov →Interventions studied
CpG-ODN
What this trial is about
To study the safety and clinical effects of intratumor injecting CpG-ODN and in situ release of tumor antigen by interventional ablation or drug-eluting beads to treat advanced solid tumors.
Who can take part
Age range
18 Years to 80 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 1
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Solid advanced malignant tumors
- Age between18 and 80 years
- Life expectancy is greater than three months
Exclusion criteria
- Benign tumor
- Life expectancy is less than three months
- Serious medical comorbidity
- Others
Where it is running
1 location listed.
- The Second Affiliated Hospital of Guangzhou Medical University - Guangzhou, Guangdong, China